Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Inhibikase Therapeutics’ SEC disclosures can feel like wading through dense clinical jargon and trial acronyms. Each 10-K details kinase-inhibitor chemistry, while a single 8-K may unveil pivotal Phase 2a data that moves the stock overnight. If you have ever searched “Inhibikase Therapeutics SEC filings explained simply” or wondered how to track “Inhibikase Therapeutics insider trading Form 4 transactions,” you already know the challenge.
Stock Titan solves it. Our AI reads every Inhibikase Therapeutics annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events explained line by line, then delivers plain-English takeaways—trial milestones, dilution risk and cash runway—in seconds. Real-time alerts flag “Inhibikase Therapeutics Form 4 insider transactions real-time,” so you see executive stock transactions Form 4 the moment they hit EDGAR. Need proxy details? We map “Inhibikase Therapeutics proxy statement executive compensation” into clear tables, and our engine links each metric to historical context.
Here’s what professionals monitor on our platform:
- Pipeline progress buried in 10-Q footnotes—converted to concise bullets
- Risk-factor shifts after FDA feedback, surfaced from 8-K filings
- Cash burn trends with “Inhibikase Therapeutics earnings report filing analysis” ready for comparison
- “Understanding Inhibikase Therapeutics SEC documents with AI” through interactive summaries
Whether you follow “Inhibikase Therapeutics quarterly earnings report 10-Q filing” for R&D spend or track “Inhibikase Therapeutics 8-K material events explained” ahead of a catalyst, our comprehensive filing coverage and expert AI put critical biotech insights one click away.
ADAR1 entities and manager Daniel Schneeberger report collectively holding 7,682,503 to 7,737,694 shares of Inhibikase Therapeutics, Inc. (IKT), representing 9.9% of the outstanding common stock as of June 30, 2025. The filing breaks down holdings across ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; and ADAR1 SPV I, LP, and includes both issued shares and shares underlying milestone warrants. The filing also discloses that additional milestone warrants (several million shares) are excluded from beneficial ownership calculations because their exercise or exchange is subject to a 9.99% ownership limitation. The report is filed under Schedule 13G/A and is signed by Daniel Schneeberger as manager and in his individual capacity.
Inhibikase Therapeutics (IKT) reported items in its Form 10-Q showing corporate and development activity ahead of a planned Phase 2b study in pulmonary arterial hypertension (PAH). The company expects to initiate a ~150‑patient Phase 2b trial in the second half of 2025 and used non‑human primate safety studies and a bioequivalence trial in healthy volunteers to set dosing.
Financing and equity actions are material: a private placement included issuance of shares and multiple warrant tranches exercisable at $1.37 and $1.49 with exercise and ownership caps, and 19,665,131 pre‑funded warrants were outstanding at June 30, 2025. An at‑the‑market agreement with HCW was terminated effective December 11, 2024; a separate Sales Agreement with Jefferies and a related shelf registration were in place as of June 27, 2025. The company acquired CorHepta, issuing shares including contingent and performance‑based shares and recognized a $7,357,294 R&D write‑off related to IPR&D.
This Schedule 13G is filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands and reports a significant passive position in Inhibikase Therapeutics common stock. The Reporting Persons beneficially own 10,950,000 shares, representing 14.7% of the outstanding class based on 74,341,540 shares outstanding as of May 1, 2025. The position is reported with shared voting and dispositive power of 10,950,000 shares and no sole voting or dispositive power.
The filing expressly excludes a Series A-1 warrant to purchase 5,475,000 shares and a Series B-1 warrant to purchase 10,068,120 shares because neither warrant is exercisable within 60 days; each warrant contains a restriction preventing beneficial ownership in excess of 19.99% immediately after exercise. The Reporting Persons certify the securities are not held to change or influence control of the issuer.
Form 4/A overview: Inhibikase Therapeutics (IKT) filed an amended Form 4 for President & Head of R&D Christopher Cabell. The filing corrects the exercise price to $2.97 on a previously reported stock-option grant covering 1,100,705 common shares originally awarded on Feb 21 2025 and expiring on Feb 21 2035. No other terms change: the options vest in three substantially equal tranches on the 2nd, 3rd and 4th anniversaries of the grant date, contingent on continued service. The amendment does not involve any share sales or purchases and therefore has no immediate cash impact on the company. It simply aligns the public record with the correct contractual terms, maintaining disclosure accuracy and avoiding potential misinterpretation of executive compensation.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
